There has been an emphasis over the last several years to identify and treat chronic kidney disease (CKD) and its complications as they evolve rather than waiting until the patient reaches end-stage renal disease (ESRD), also known as CKD stage 5. The number of patients who will be identified and prescribed therapies for complications such as secondary hyperparathyroidism (SHPT) is greater than initially proposed.
School of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, Univerisity of North Carolina, Chapel Hill, NC 27599-7155, USA. melanie_joy@med.unc.edu
